Top Markets
#1 Decred Decred +8.72%
#2 Wibx Wibx +8.37%
#3 Status Status +7.35%
#4 SkyAI SkyAI +5.40%
#5 aelf aelf +5.26%
#6 MarsCoin MarsCoin +5.08%
#7 TRIA TRIA +4.98%
#8 Rei Rei +4.63%
#9 Wrapped Flare Wrapped Flare +4.46%
#10 DexNet DexNet +3.98%
Coin of the day
Decred Decred
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
Xếp hạng trong cổ phiếu #30761
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Giá cổ phiếu
$0.10794012
Đồng bộ lần cuối: 2022-12-15
Vốn hóa thị trường
$15.65M
Thay đổi (1 ngày)
-17.06%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Clovis Oncology, Inc. (C6O)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Clovis Oncology, Inc. (C6O)
Giá đóng cửa cao nhất: $0.23 vào 2022-12-01

Giá đóng cửa thấp nhất: $13.25 vào 2019-11-01
Lịch sử giá cổ phiếu của Clovis Oncology, Inc. từ 2019 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2022 -92.16%
2021 -41.81%
2020 -57.55%
2019 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.89 35.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $996.61 51.72%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $116.42 -20.02%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.07%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $257.75 14.92%
BE